<DOC>
	<DOC>NCT00369070</DOC>
	<brief_summary>The purpose of this study is to estimate the difference in objective response rates between each paclitaxel/carboplatin plus AMG 706 arm (Arm A and B) and paclitaxel/carboplatin plus bevacizumab arm (Arm C) in subjects with advanced non-squamous NSCLC.</brief_summary>
	<brief_title>A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Men or women 18 years or older with histologically or cytologically confirmed advanced nonsquamous NSCLC (unresectable stage IIIB with pericardial or pleural effusion or stage IV/recurrent) Measureable disease per RECIST criteria modified ECOG performance status of 0 or 1 Ability to take oral medications Competent to give written informed consent Current or prior history of CNS metastases Any prior chemotherapy for advanced NSCLC History of pulmonary hemorrhage or gross hemoptysis within 6 months prior to randomization Prior targeted therapies Known history of allergy or hypersensitivity to paclitaxel or carboplatin History of arterial or venous thrombosis within 52 weeks prior to randomization History of bleeding diathesis or nonpulmonary bleeding within 14 days prior to randomization Peripheral neuropathy &gt; grade 1 per CTCAE Version 3.0 Myocardial infarction, cerebrovascular accident, grade 2 or greater peripheral vascular disease, transient ischemic attack, congestive heart failure, percutaneous transluminal coronary angioplasty/stent, ongoing arrythmias requiring medication or unstable angina within 52 weeks prior to randomization Any kind of disorder that compromises the ability of the subject to comply with the study procedures Uncontrolled hypertension as defined by resting blood pressure &gt; 150/90 mm Hg. Antihypertensive medications are allowed if hypertension is stably controlled at the time of randomization. Participation in therapeutic clinical trials or currently receiving other investigational treatment(s) within 30 days prior to randomization Pregnant or breast feeding women Known to be HIV, hepatitis B surface antigen, or hepatitis C positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>AMG 706</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Paclitaxel and Carboplatin</keyword>
	<keyword>Randomized</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
</DOC>